Toby Jane Hindin, EdD, M.Ed. MS
Toby Jane Hindin, EdD, M.Ed. MS
Dr. Hindin is Editor-in-Chief of Applied Clinical Trials magazine. She received her doctorate and M.Ed from Columbia University. While at Columbia, Dr. Hindin developed curriculum and education materials in her role as implementation and project coordinator for the LiFE Project, part of an NIH grant. Her doctoral research focused on designing, developing and implementing an innovative media and nutrition education program. She is well published in peer review science and education journals. While at Columbia she received the Orrea Pye Fellowship and Helena Ebert Duncombe award. She has spent the last 6.5 years in trade publishing including developing CME publications, teleconferences, and roundtables. Prior to her years at Columbia, Dr. Hindin worked as a nutritional consultant and freelance writer/editor/ghost writer.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
